Skip Navigation LinksHome > May 2012 - Volume 112 - Issue 5 > New Drug Approved for Advanced Renal Cell Cancer
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000414312.49083.9b
Drug Watch

New Drug Approved for Advanced Renal Cell Cancer

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* Axitinib (Inlyta), a tyrosine kinase inhibitor, has recently been approved for the treatment of advanced kidney cancer when other therapy hasn't been successful. Taken orally twice a day, axitinib prevents angiogenesis, tumor growth, and cancer progression.

* Common adverse effects include diarrhea, hypertension, fatigue, anorexia, nausea, loss of voice, hand–foot syndrome, weight loss, vomiting, weakness, and constipation.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Level Metrics